Visual Studio Code has been my favorite programming text editor and integrated development environment (IDE) for years. Even ...

Hands on with GitHub’s open-source tool kit for steering AI coding agents by combining detailed specifications and a human in ...

As SQL development increasingly becomes part of full-stack workflows, developers are looking for ways to simplify their tooling without compromising capability. While SQL Server Management Studio ...

PINECREST, FLA. (WSVN) - A python caused some trouble on a South Florida road but it wasn’t long before officers scooped in to save the day. The 14-foot beast was found on US-1and 98th Street in ...

His snake eyes were bigger than his stomach. Florida might have a new ally in the ongoing fight against the invasive Burmese python scourge — chilly weather. Researchers who track the elusive and ...

Japanese semiconductor equipment maker Tokyo Electron Limited (TEL) will soon establish a new development site in Bengaluru, Karnataka IT minister Priyank Kharge said on Tuesday. The ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Joby announced Wednesday it is partnering with Uber to offer Blade helicopter flights as soon as next year. Blade, which will remain a division of Joby following its acquisition last month, will ...

As arguably one of the most subjective movie genres, opinions on the best comedy films aren't always universally agreed upon. The constant evolution of comedy as a movie genre — including the ...

(Reuters) -Pfizer (PFE) said on Monday it would acquire weight-loss drug developer Metsera (MTSR) for up to $4.9 billion to secure its position in the lucrative obesity treatment market.

What if the very tools designed to empower developers began to outpace them? OpenAI’s Codex 2.0, powered by the innovative GPD5 High model, has done more than just refine AI-assisted programming, it ...

Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them. MET-233i is being ...